LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Tumors With CDK4/6 Pathway Activation
Interventions: DRUG: LEE011
Sponsor: Novartis Pharmaceuticals